Accessibility Menu
Biofrontera logo

Biofrontera(NASDAQ) BFRI

Market Cap$15.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 YearN/A
1 Year+14%
1 Month+18%
$1.23
+3.36%
+0.04Today
After hours$1.24+$0.01 (+0.81%)
Biofrontera last closing stock price
MetricPriceDate
Last closeUSD 1.192026-08-03
Biofrontera stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.33%USD 1.052026-07-27
1 month+17.82%USD 1.012026-07-02
3 month+3.48%USD 1.152026-05-05
Year to date+108.77%USD 0.572025-12-31
1 year+14.42%USD 1.042025-08-01
3 year-90.1%USD 12.022023-08-04
Since inception-98.65%USD 88.202021-10-29

Biofrontera Financials at a Glance

Market Cap

$15.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$43.20M

Net Income (TTM)

-$11.09M

EPS (TTM)

-$1.11

P/E Ratio

-1.07

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.23

Volume

516,227.201

Open

$1.19

Previous Close

$1.22

Daily Range

$1.18 - $1.26

52-Week Range

$0.55 - $1.27

Estimated Earnings Date

Aug 12, 2026

BFRI News

featured-earnings-leadership-highlights.png

Biofrontera Q2 Revenue Jumps 15%

Motley Fool Markets TeamAug 14, 2025
Foolcom-Featured.png

Biofrontera Revenue Jumps 15% in Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biofrontera

Biofrontera helps doctors treat common skin conditions like actinic keratosis. Its main products combine a prescription cream and a special lamp for targeted therapy. These treatments are used in dermatology clinics to improve patient outcomes.

Skin in the Game: Products and Services

  • Ameluz (≈100% revenue): Prescription cream for treating actinic keratosis, a pre-cancerous skin condition, used mainly by dermatologists.
  • RhodoLED Lamp Series (included in Ameluz revenue): Medical lamps that activate Ameluz during photodynamic therapy, enabling in-office treatment for mild-to-moderate skin lesions.
  • Xepi (divested in November 2025): Prescription cream for impetigo, a bacterial skin infection, no longer part of the portfolio.
  • Clinical Trials: Research on expanding Ameluz use to other skin conditions, such as acne and superficial basal cell carcinoma.
  • Direct Sales Model: Products sold directly to dermatology offices and groups across the United States.

Growth Spurts: Expansion Moves and Milestones

  • Acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera Group in October 2025.
  • Divested Xepi product line in November 2025 for upfront and milestone payments.
  • Launched RhodoLED XL lamp in June 2024, expanding treatment area options.
  • Secured new supply agreement with Midas Pharma GmbH in 2025 for ingredient sourcing.
  • Expanded clinical trials for new Ameluz indications throughout 2024 and 2025.

Why Biofrontera Stands Out

Biofrontera controls both the drug and device for its main therapy, offering a bundled solution for clinics. Its direct sales approach targets dermatology practices, reducing reliance on distributors. The company holds patents extending to 2043, supporting its market position in photodynamic therapy.

Five Things You Need to Know

  • Product revenue was $41.7 million in 2025, up 11.8% from 2024.
  • Net loss improved to $(10.5) million in 2025 from $(17.8) million in 2024.
  • Adjusted EBITDA margin improved to (25.4%) in 2025 from (40.9%) in 2024.
  • Cash and cash equivalents were $6.4 million as of December 31, 2025.

Bottom Line

Biofrontera has focused its business on dermatology treatments and direct sales to clinics. The company’s evolution shows adaptability, but ongoing funding needs remain a key challenge.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

92

CEO

Hermann Lübbert, PhD

Website

www.biofrontera-us.com

Headquarters

Woburn, MA 01801, US

BFRI Financials

Key Financial Metrics (TTM)

Gross Margin

82.79%

Operating Margin

-20.64%

Net Income Margin

-25.66%

Return on Equity

-476.72%

Return on Capital

-54.97%

Return on Assets

-44.72%

Earnings Yield

-93.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.80M

Volume

516.23K

Avg. Volume

313.74K

Financials (TTM)

Gross Profit

$35.77M

Operating Income

-$8.92M

EBITDA

-$10.00M

Operating Cash Flow

-$9.31M

Capital Expenditure

-$4.00K

Free Cash Flow

-$9.32M

Cash & ST Invst.

$6.32M

Total Debt

$7.72M

Biofrontera Performance Analysis

Biofrontera annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 28,674,00019.0%
20232023-12-31USD 34,071,00018.8%
20242024-12-31USD 37,321,0009.5%
20252025-12-31USD 41,705,00011.7%
Biofrontera sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.1%
Q32025-09-30-22.6%
Q42025-12-31144.7%
Q12026-03-31-41.0%
Biofrontera annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.61-98.6%
20232023-12-31USD -13.022050.4%
20242024-12-31USD -3.22-75.3%
20252025-12-31USD -1.04-67.8%
Biofrontera sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3025.0%
Q32025-09-30-8.8%
Q42025-12-31177.4%
Q12026-03-31-185.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$10.08M

+17.4%

Gross Profit

$8.25M

+56.0%

Gross Margin

81.84%

N/A

Market Cap

$15.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$165.61K

N/A

Employees

92

N/A

Net Income

-$4.75M

-13.1%

EBITDA

-$4.69M

-21.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.32M

+252.5%

Total Debt

$7.72M

+58.8%

Accounts Receivable

$3.88M

-3.8%

Inventory

$1.23M

-81.1%

Long Term Debt

$7.22M

+62.7%

Short Term Debt

$506.00K

+18.8%

Return on Assets

-44.72%

N/A

Return on Invested Capital

-64.33%

N/A

Free Cash Flow

-$75.00K

+98.2%

Operating Cash Flow

-$70.00K

+98.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COCPCocrystal Pharma, Inc.
$0.98+4.28%
SNSESensei Biotherapeutics, Inc.
$13.85-22.28%
AYTUAytu BioPharma, Inc.
$2.21-1.78%
EVGNEvogene Ltd.
$0.65+21.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About BFRI

What is the current price of Biofrontera?

Biofrontera is trading at $1.22 per share.

What is the 52-week range for Biofrontera?

Over the past 52 weeks, Biofrontera has traded between $0.55 and $1.27.

How much debt does Biofrontera have?

As of the most recent reporting period, Biofrontera reported total debt of $7.72M.

How much cash does Biofrontera have on hand?

Biofrontera reported $6.32M in cash and cash equivalents in its most recent financial results.

What is Biofrontera’s dividend yield?

Biofrontera does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services